The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
A study compared second-line treatment options for essential thrombocythemia (ET) and found that ropeginterferon alfa-2b “outperformed” anagrelide in both efficacy and safety outcomes.
Follow-up results from the BELLWAVE-003 study assessing nemtabrutinib in patients with hematologic malignancies showed continued antitumor activity and no new safety concerns with
Andrew Kuykendall, MD, SOHO Insider MPN podcast host, and assistant professor in the Department of Malignant Hematology at Moffitt Cancer Center, delivers live
A post-hoc analysis found that the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) produced durable remissions and maintained a favorable benefit-risk profile
Meet Jesus Gonzalez Lugo, MD, an assistant professor of medicine at the University of Kansas and a 2024 SOHO Young Investigator Program (YIP)
Researchers conducted a proof-of-concept study for genetically redirecting T cells, offering a potential immunotherapy target for acute myeloid leukemia (AML) and myelodysplastic syndromes
Patients with newly-diagnosed multiple myeloma (MM) treated with isatuximab plus carfilzomib, lenalidomide, dexamethasone (IsaKRD) in induction, consolidation, and light consolidation phases saw sustained measurable
In patients with polycythemia vera (PV) receiving standard of care (SOC) therapy, treatment with rusfertide resulted in a statistically significant reduction in the
Sintilimab plus ifosfamide, carboplatin, and etoposide (ICE) as second-line treatment of classical Hodgkin lymphoma (cHL) significantly improved complete remission rates (CRRs) compared with
A generic version of nilotinib (Tasigna®) entered the US market on May 27, 2025, with 180 days of exclusivity, reported Apotex, the pharmaceutical
